| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $48.5M | — | +11.2% |
| SG&A Expense | $11.2M | — | -27.2% |
| Operating Income | -$59.8M | — | -1.2% |
| Net Income | -$58.2M | — | -1.2% |
| EPS (Basic) | -$0.94 | — | +13.8% |
| EPS (Diluted) | -$0.94 | — | +13.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $169.5M | -19.2% | +22.1% |
| Current Assets | $175.3M | -18.4% | +22.8% |
| Total Assets | $306.0M | -13.0% | +2.7% |
| Current Liabilities | $49.6M | +8.9% | +60.6% |
| Total Liabilities | $193.9M | -0.1% | +2.6% |
| Stockholders' Equity | $112.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$40.0M | — | -37.6% |
| Capital Expenditures | $942K | — | +248.9% |
| Investing Cash Flow | -$942K | — | -248.9% |
| Financing Cash Flow | $619K | — | +399.2% |
| Free Cash Flow | -$41.0M | — | -39.5% |
| +3.0% |